- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Nanoscope Therapeutics Announces the Appointment of Samuel Barone, MD, as Chief Medical Officer
Barone is a former FDA officer.
Samuel Barone, MD, joins Nanoscope Therapeutics Inc. as chief medical officer.
Nanoscope Therapeutics announced the appointment in a press release. Barone comes to Nanoscope from Gemini Therapeutics, where he served as chief medical officer.
"We are thrilled to welcome Dr. Barone to the Nanoscope team. The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, co-founder and CEO of Nanoscope. "Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner."
"Nanoscope has the potential to impact the treatment landscape with its gene-agnostic, sight-restoring optogenetic therapies and bring these transformative therapeutic options to patients with severe vision loss due to inherited retinal diseases, for which there are no restorative therapies available," said Dr. Barone. "I look forward to taking MCO-010 through approval and advancing Nanoscope's follow-on assets to the clinic."
Barone is a board-certified ophthalmologist and vitreoretinal surgeon. He also has experience with clinical development.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
